Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Non-Randomized, Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus mRNA-1647 Vaccine Including a Booster Dose in a Subset of Participants Who Completed Study mRNA-1647-P202

NCT04975893 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT04975893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04975893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Non-Randomized, Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus mRNA-1647 Vaccine Including a Booster Dose in a Subset of Participants Who Completed Study mRNA-1647-P202
Lead sponsor
ModernaTX, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 18, 2021
Completion date
January 19, 2026
Enrollment
135 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus infection